Monthly Archives: February 2021

According to Allergy & Asthma Network, 7.3 percent of adults in the United States have atopic dermatitis, and actress Tiffany Haddish just revealed that she is part of that number in this weeks issue of People. If youre in the same boat, the star offered up some insight on the product she uses to soothe her irritated skin. And to our surprise, its extremely affordable.

So beauty-wise I wash my face with the same thing I wash my body with, which is this pure spearmint gum, turpentine soap mixed with olive oil that I found on Amazon, she tells People. It gets rid of eczema, dry spots, rashes and stuff like that. According to Haddish, the product, which she later pins as Diamond G Forest Products Turpentine Soap ($8), is so good, I had told one of my co-stars [about it] because she was saying her baby had eczema. I said, Try this soap. So I gave it to her. She was like, Tiffany its good, the eczemas gone!'

The Like a Boss stars other favorite skin-care product includes another all-natural must-have that is known for its skin-silkening properties: coconut oil. I soak my face in that, wash it off and then Ill use castor oil on my eyelids to help make my eyelashes grow, she says. When shes craving a more luxurious makeup-melter, shell reach for the Tatcha Camellia Oil ($48), which leaves the skin softer than ever come morning.

Like her beauty routine, Haddishs hair-care lineup is so low maintenance, she recently decided to shave her head, which, according to People, she says shes always wanted to do. Just loving my new look thought Id share it with yall, she recently captioned an Instagram post. The best part is when water hits my head it feels like kisses from God.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

See the original post:
Tiffany Haddish Uses This $9 Soap to Treat Her Eczema - NewBeauty Magazine

If topical corticosteroids for atopic dermatitis do not seem to work, explore how they are being used (quantity, frequency, duration of application), the appropriateness of steroid potency prescribed, the ongoing use of moisturisers, the presence of other skin infections, and potential allergen exposure

Many other conditions mimic atopic dermatitis in children, so the diagnosis warrants frequent review to assess for treatment response, especially if the skin lesions look atypical

Refer patients who do not show clinical improvement or who experience frequent, severe flares while on confirmed, adequate topical therapyor patients for whom the diagnosis is unclearto a paediatric dermatologist or paediatrician to consider the use of second line therapy or to explore alternative diagnoses

A 1 year old boy visits your clinic. He received a diagnosis of atopic dermatitis six months ago. On return visit today, his rash and pruritus have worsened despite intermittent application of a small quantity of hydrocortisone 1% cream. His sleep has been constantly interrupted by scratching. On examination, his skin is dry with excoriated, erythematous plaques on his limbs and trunk. His parents want to stop using topical corticosteroids (TCS) out of concern for side effects and because the cream is not working.

Atopic dermatitis, a type of eczema, is the most commonly diagnosed paediatric dermatosis (box 1), affecting about 20% of children.2

Pruritus

Acute: Erythematous papules, scaly patches with oedema and excoriations that are distributed in age related patterns (eg, face, trunk, and extensor surfaces of extremities in infants, flexural surfaces in children)

Chronic: Lichenification, dyspigmentation

Emollients are essential treatment for acute flare and for maintenance, and TCS continue to be the first-line drug treatment.23 Sub-optimal management results in poor control of symptoms, which negatively affects quality

Excerpt from:
Atopic dermatitis in children: when topical steroid treatment does not work - The BMJ

MANILA, Philippines Atopic dermatitis, more commonly known as eczema, is one of the most common inflammatory skin conditions affecting people of all ages, especially children, throughout the world.

According to a 2017 article published by the American Journal of Managed Care, the incidence rate of the disease has reportedly doubled or tripled in industrialized countries since the 1970s. Of this, 15% to 20% are children.

In the Philippines, records from Philippine Dermatological Society-accredited institutions show that 65.1% of outpatients with eczema are children aged 1 to 12 years, and 24% are infants who are less than 1 year old.

Young as they are, children cannot fully understand the effects of eczema, especially if untreated, on the quality of their lives. It is therefore imperative for moms to take immediate steps to address this skin concern.

It begins by knowing what exactly eczema is, from its causes to diagnosis, even myths surrounding it, and finally proper treatment, especially now in the face of a health crisis.

Dr. Ma. Victoria Dizon, pediatric dermatologist, lends her expertise to help moms better care for their kids with eczema.

Eczema is characterized by a rash that is itchy and red.

According to Dr. Dizon, eczema is characterized by a rash that is itchy and red, which are mostly identified as contact or seborrheic dermatitis, among others.

In worse cases, it can develop tiny blisters that lead to an oozing weeping wound, she shares.

She adds to watch out for visible signs including:

Environment triggers like heat, sweat, dust and pollution, can challenge the sensitive skin and cause the eczema.

While genetics play a big part in developing eczema, there are other important factors that cause it.

Environment triggers like heat, sweat, dust and pollution, can challenge the sensitive skin and cause eczema. The causes of eczema in children may differ from the adults because kids may have different allergen exposures based on their activities, like outdoor sports for example, while adults have occupation-related causes, Dr. Dizon explains.

Given genetic propensity and environmental factors that lead to eczema, this sheds light on the misconception that it is contagious. Eczema simply isnt.

One way to mitigate or prevent the occurrence of eczema flares is to use mild, moisturizing soaps or cleaners as hand soaps.

Significant shifts in everyday life have been observed as a result of the global health crisis, including constant handwashing and frequent use of alcohols and other disinfectants.

These have become major triggers for eczema breakouts, as the said products strip away the skins natural oils and interrupt the skin barrier by increasing its pH levels, directly resulting in alkalinity.

One way to mitigate or prevent the occurrence of eczema flares is to use mild, moisturizing soaps or cleaners as hand soaps.

It is equally important to restrict the use of alcohols and other disinfectants and to reserve them only when soap and water are not readily available.

Frequent moisturizing of the skin will also function as a preventive and repairing step to address eczema problem, adds Dr. Dizon.

When caring for children with eczema, moms must always remember that they are dealing with sensitive skin.

As the primary caregivers of children with eczema, moms must always remember one thing: They are dealing with children who have sensitive skin.

With this, Dr. Dizon shares tips to makes sure that their childs skin is able to repair itself and stay healthy:

Lastly, moms must also be more discerning with the types of products they use to treat eczema.

When it comes to topical medications, moms need to be more scrutinizing.

When it comes to topical medications, Dr. Dizon advises moms to be more scrutinizing.

They should look for medicines that are mild or not too strong for use on childrens skin. They should also consider the choice of topical medication that is recommended by the doctora pediatrician, a family practice doctor, or a dermatologist/pediatric dermatologist), she says.

Avoid topical medications that can irritate that delicate skin. Never use topical medications that are too strong for the skin and those that can cause an allergic reaction, she continues.

When it comes to eczema relief, moms can trust Bepanthen.

When it comes to healing and regeneration of vulnerable skin during and following eczema flare-ups, moms can choose Bepanthen products.

A steroid-free spot treatment, Bepanthen Itch Relief Cream contains dexpanthenol, a highly absorbent fatty emulsion that relieves eczema itch in as much as 30 minutes while repairing damaged skin barrier.

On the other hand, Bepanthen Sensidaily is formulated with prebiotics that support the skin's natural microflora, as well as niacinamide that helps regenerate the skin from within.

With these benefits, Bepanthen Sensidaily is clinically tested to help keep the skin flare-free for up to three months with regular use. It also helps keep the skin deeply hydrated which is essential to keeping the skin barrier strong and healthy.

Together, Bepanthen Sensidaily and Bepanthen Itch Relief Cream provide moms an eczema management solution for their children.

For more information, visit the official Facebook account here. Bepanthen is available online via Shopee and Lazada, and in leading drugstores nationwide.

If symptoms persist, consult your doctor.

ASC Reference Code: B068P020221BS

The rest is here:
Skin expert gives mommy advice on caring for children with eczema - Philstar.com

TOKYO, Feb. 18, 2021 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin"), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies,announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.

KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company's patented POTELLIGENT defucosylation technology to enhance its antibody dependent cellular cytotoxicity(ADCC) activity2. The combination of ADCC and antagonist activity against OX40 may suppress inflammatory responses found to be the cause of atopic dermatitis3-6.

The Phase 2 study was a multicenter, randomized, double-blind and placebo-controlled clinical study conducted in Japan, the United States, Canada, and Germany to investigate the efficacy and safety of KHK4083. Globally, 274 patients with moderate to severe atopic dermatitis, who were not adequately controlled with topical agents, were enrolled in the study.

In this study, all KHK4083 cohorts achieved superiority to placebo cohort for the primary endpoint of "percent change from baseline in Eczema Area and Severity Index (EASI) 7 at 16 weeks" with statistical significance. In addition, there was significant difference in "the percentage of patients achieving an EASI-75 (EASI score of 75% or greater improvement from baseline) at 16 weeks" and "the percentage of patients achieving the Investigator's Global Assessment (IGA) of 0 or 1 with an improvement of 2 points or more at 16 weeks" in all KHK4083 cohorts compared to the placebo cohort. Further improvement in efficacy of KHK4083 was observed after week 16. Common treatment-emergent adverse events for KHK4083 cohorts were pyrexia, nasopharyngitis, worsening of atopic dermatitis and chills during the first 16 weeks. No deaths were observed in the study.

"The results of the KHK4083 Phase 2 study show that OX40 is a relevant target for atopic dermatitis and may provide a new treatment paradigm," said the lead investigator of this study, Dr. Emma Guttman-Yassky, MD./PhD., System Chair for the Department of Dermatology and Waldman Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai and Director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at Mount Sinai. "In addition to the primary endpoint, this study also showed progressive improvement in efficacy by continuous KHK4083 administration beyond 16 weeks andthe potential for long-term sustained therapeutic effect after the completion of KHK4083 treatment."

"We are very pleased with the results of this studyshowingefficacy and safety of KHK4083 in chronic, recurrent, moderate to severe atopic dermatitis," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of Global R&D Division of Kyowa Kirin. "We look forward to sharing the results of the full analysis in the near future. I would like to express my deep gratitude to the medical professionals and patients for their participation in the study. We will continue KHK4083 development with the hope it can help patients in need."

The full results of the study are planned to be presented through future academic conferences and publications.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

About Atopic DermatitisAtopic dermatitis is a disease in which the main lesion is an itchy eczema that repeatedly flares up and flares down, and many patients have a predisposition to atopic dermatitis (family and previous history, predisposition to produce IgE antibodies). It is an eczematous disease with a characteristic symmetrical distribution, and the site of predilection differs according to age. Characteristic eczematous lesions that develop in infancy or early childhood, remit in childhood, or recur without remission, and persist into adulthood, are seen chronically.

About OX40OX40 is a co-stimulatory molecule that is one of the tumor necrosis factor receptor (TNFR) family member and plays an important role in maintaining T cell proliferation and survival by inhibiting apoptosis and in the formation of memory T cells. OX40 is also expressed on the surface of effector T cells (CD4 positive) activated by antigens. It has been reported that effector T cells expressing OX40 are present in the lesions of atopic dermatitis3-6.

About Eczema Area and Severity IndexEASIEASI is an internationally used classification of atopic dermatitis severity and is recommended for use by Harmonising Outcome Measures for Eczema, an international group for standardizing clinical trial outcomes in atopic dermatitis7.

About Kyowa KirinKyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company witha 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions Japan, Asia Pacific, North America and EMEA/International we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com.

References

SOURCE Kyowa Kirin Co., Ltd.

https://www.kyowakirin.com

Read the original post:
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis - PRNewswire

Innovation in K-Beauty never ceases to amaze us. In addition to developing ingenious regimens and easy hacks, Korean beauty brands have introduced us to some game-changing skincare ingredients including snail mucin, propolis, and bamboo.

The newest buzz-worthy ingredient on top of the K-Beauty 2021 trend forecast? Heartleaf (scientifically known as houttuynia cordata), a flavonoid and flowering plant native to Southeast Asia, according to board-certified plastic surgeon Dr. Michele Koo, MD.

In Southeast Asia, houttuynia cordata is eaten as a leafy vegetable that contains antioxidant, anti-bacterial, and anti-inflammatory properties, Dr. Koo explains. Its potential for skincare is promoted because of its anti-inflammatory (think blemishes, rashes, eczema) and hydrating properties.

But thats only the beginning. So, we tapped Dr. Koo (plus a few other skincare pros) to share all the ins-and-outs of the ingredient, as well as some easy ways to introduce it into your routine.

According to a 2014 study published in Pharmacognosy Review, heartleaf is traditionally used for medicinal purposes in North-East India and China. Raw leaves and extract from the plant are consumed to purify the blood and to relieve inflammatory conditions in the body.

However, its worth noting that heartleaf can also be used topically. A 2010 study published in the Chonnam Medical Journal suggests that the plant can treat snake bites, as well as skin disorders such as acne and atopic dermatitis.

The plant has been shown to have antioxidant and anti-inflammatory properties, says Dr. Kim. However, whether that translates to smoothing rough, angry, and fickle skin (or removing blemishes) is still not known, she notes, citing the need for additional research. In other words, dont think of this as a cure-all ingredient just yet.

Sensitive and dry skin types are best suited for products containing heartleaf because the ingredient is a humectant, meaning it moisturizes, and has soothing, anti-inflammatory properties, explains Dr. Koo.

New York City-based dermatologist Dr. Debra Jaliman, MD, warns that some people with extremely sensitive skin could have adverse reactions when using products that contain heartleaf. Which is why she recommends doing a patch test on your arm first to see how your skin reacts. Some people get tingling from this ingredient, Dr. Jaliman explains. If you have very red skin, rosacea, or bad eczema, you may want to avoid it."

Additionally, board-certified dermatologist Dr. Lavanya Krishnan, MD, advises against using heartleaf products if you have allergies to sulfonamides, which are medicines used to treat bacterial infections.

Because of its soothing and anti-inflammatory properties, heartleaf is often incorporated into skincare products like facial masks, toners, and creams, says Dr. Koo. And thanks to its antibacterial properties, its can be a helpful ingredient in acne products for sensitive skin, adds Dr. Krishnan.

But before adding some heartleaf-infused products to your shopping cart, Dr. Koo advises remembering that the extraction process of the plant can vary by brand, which might impact the quality of the product youre using.

It is extremely important to select products from brands that are very transparent about their production processes, and hold themselves to a higher standard, she says. Sometimes the extraction methodology contains residual toxic ingredients and can actually be harmful. Make sure you trust the product line to deliver clean, pure healthy ingredients.

RELATED: Why Everyone Is Trying the 3-Second Rule of Korean Beauty

Boost your skins moisture content with this oil-free cream. It combines heartleaf extract with calming aloe vera, and barrier-protecting prickly pear extract.

Buy It ($23)

Upgrade your sheet mask stash with this calming bamboo jelly moisture mask, which utilizes heartleaf as a main ingredient in order to bring balance, and a blast of moisture to dry skin.

Buy It ($15)

Send dullness, blemishes and redness packing with these heartleaf extract-infused spot treatment pads. Reviewers say theyre great for sensitive skin, too.

$20 at Amazon

By gently clearing blackheads and removing excess oil from the skin, this cleanser is great for acne-prone skin. And it wont leave your face inflamed or dry after use.

Buy It ($20)

See the rest here:
Whats Heartleaf? It's the Newest & Buzziest K-Beauty Ingredient - PureWow

Mild-to-moderate atopic dermatitis is a chronic inflammatory skin disease often confined to the flexural surfaces of the body and usually begins in childhood. This skin disease affects a large percentage of the worlds population. Atopic dermatitis is also known as eczema which is characterized by itching, swelling, dry skin, redness, vesicle formation, crusting, cracking, scaling and weeping. Atopic dermatitis is a long-term skin disease, which is classified into different types depending on the skin condition such as contact eczema, allergic contact eczema, neurodermatitis, dyshidrotic eczema, nummular eczema, stasis dermatitis and seborrheic eczema. Multiple factors are responsible for mild-to-moderate atopic dermatitis which include low humidity, cold weather, seasonal allergies, and exposure to harsh soaps and detergents.

Get Sample Copy of Report @https://www.persistencemarketresearch.co/samples/15379

Mild-to-Moderate Atopic Dermatitis Treatment Market: Drivers and Restraints

Large patient population and new product launches are factors projected to drive the growth of mild-to-moderate atopic dermatitis treatment market globally. According to the United Nations Population Fund (UNFPA), the global population is growing at a rate of 1.1%. Climatic changes and large pipeline products are factors which are estimated to fuel the growth of this market. However, stringent regulations for product approvals and generic competition are the factors which hinder the market growth of mild-to-moderate atopic treatment market globally.

Mild-to-Moderate Atopic Dermatitis Treatment Market: Segmentation

By treatment type the mild-to-moderate atopic dermatitis treatment market can be segmented into

By distribution channel the mild-to-moderate atopic dermatitis treatment market can be segmented into

Drug treatment can further be segmented into antihistamines, antibiotics, emollients, corticosteroids, and calcineurin inhibitors. Topical corticosteroids are the standard treatment for most patients with atopic dermatitis for more than 50 to 60 years. Calcineurin inhibitors are used as second line treatment drug for atopic dermatitis. Recently the U.S. Food and Drug Administration has approved Eucrisa a topical treatment for children and adults with mild-to-moderate atopic dermatitis. Eucrisa works differently than other topical treatments on the market.

Mild-to-Moderate Atopic Dermatitis Treatment Market: Overview

The medication treatment of the skin disease depends on the duration, pattern, and severity of the skin lesions. Except drug therapy, atopic dermatitis is treated with ultraviolet light therapy. According to the American Academy of Dermatology (AAD), the atopic dermatitis that emerges in adults is often different and more severe than infants and children. According to Anacor Pharmaceuticals, Inc., atopic dermatitis is estimated to affect about 18% of infants and children in developed countries. These disease often becomes milder with age.

Want a sneak peek into the Mild To Moderate Atopic Dermatitis Treatment Market? Access the Table of Content of Mild To Moderate Atopic Dermatitis Treatment Market report! @https://www.persistencemarketresearch.co/toc/15379

Mild-to-Moderate Atopic Dermatitis Treatment Market: Region-wise Outlook

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and Middle East and Africa. North America leads the market for mid-to-moderate atopic dermatitis reasons being lifestyle changes, new product innovations, and early treatment adoption. A large proportion of the U.S. population has symptoms of eczema. According to the National Eczema Association in the U.S., approximately 30 million people are living with eczema, and the prevalence rate of childhood eczema is 10.8%. Europe is the second leading market for mild-to-moderate atopic dermatitis treatment due to development activities and large research base. The Asia Pacific market is also expected to grow at a higher rate owing to changing lifestyle, large target patient pool, rapid population growth, adoption of western lifestyle, and growth in research and development. These factor are likely to drive the market growth of mild-to-moderate atopic dermatitis treatment market during the forecast period globally.

Request Customization of this Report @https://www.persistencemarketresearch.co/request-customization/15379

Mild-to-Moderate Atopic Dermatitis Treatment Market: Key Players

The major players in mild-to-moderate atopic dermatitis treatment market include Anacor Pharmaceuticals, Inc., Astellas Pharma Inc., Meda Pharmaceuticals, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi S.A., and Valeant Pharmaceuticals International, Inc.. The robust drug pipeline shows that manufacturers see a large potential market for mild-to-moderate atopic dermatitis treatments. For instance, Anacor Pharmaceuticals is developing a drug, crisaborole which is a non-steroidal topical anti-inflammatory for mild-to-moderate atopic dermatitis which can have a significant utilization. Dupilumab is expected to be approved for the treatment of moderate to severe atopic dermatitis in adults.

About Us

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping business ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact Us:

Persistence Market Research (PMR)

Address 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales [emailprotected]

https://neighborwebsj.com/

View original post here:
Mild To Moderate Atopic Dermatitis Treatment Market to Stand Tall from 2020 to 2030 NeighborWebSJ - NeighborWebSJ